Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1720-8319
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents? ; volume:33 ; number:11 ; day:15 ; month:10 ; year:2021 ; pages:3151-3160 ; date:11.2021
Aging clinical and experimental research ; 33, Heft 11 (15.10.2021), 3151-3160, 11.2021
- Urheber
-
Oyebanji, Oladayo A.
Wilson, Brigid
Keresztesy, Debbie
Carias, Lenore
Wilk, Dennis
Payne, Michael
Aung, Htin
Denis, Kerri St
Lam, Evan C.
Rowley, Christopher F.
Berry, Sarah D.
Cameron, Cheryl M.
Cameron, Mark J.
Schmader, Kenneth E.
Balazs, Alejandro B.
King, Christopher L.
Canaday, David H.
Gravenstein, Stefan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40520-021-01987-9
- URN
-
urn:nbn:de:101:1-2022012620425809077709
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Oyebanji, Oladayo A.
- Wilson, Brigid
- Keresztesy, Debbie
- Carias, Lenore
- Wilk, Dennis
- Payne, Michael
- Aung, Htin
- Denis, Kerri St
- Lam, Evan C.
- Rowley, Christopher F.
- Berry, Sarah D.
- Cameron, Cheryl M.
- Cameron, Mark J.
- Schmader, Kenneth E.
- Balazs, Alejandro B.
- King, Christopher L.
- Canaday, David H.
- Gravenstein, Stefan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis